Destiny Pharma (DEST) RNS Announcements

Add to Alert list
Date Time Source Announcement
03 Feb 2021 07:00 AM
RNS
Brazilian Patent Granted for XF-73 nasal gel
02 Feb 2021 07:05 AM
RNS
Destiny Pharma to join panel discussion at LSX
02 Feb 2021 07:00 AM
RNS
Destiny Pharma Appoints Professor Mark Wilcox
21 Jan 2021 04:41 PM
RNS
Second Price Monitoring Extn
21 Jan 2021 04:35 PM
RNS
Price Monitoring Extension
21 Jan 2021 04:31 PM
RNS
Grant of Share Options
21 Jan 2021 08:28 AM
RNS
Destiny Pharma Investor Presentation
14 Jan 2021 11:05 AM
RNS
Second Price Monitoring Extn
14 Jan 2021 11:00 AM
RNS
Price Monitoring Extension
07 Jan 2021 11:05 AM
RNS
Second Price Monitoring Extn
07 Jan 2021 11:00 AM
RNS
Price Monitoring Extension
07 Jan 2021 07:00 AM
RNS
Destiny Pharma: Directors Dealings
06 Jan 2021 08:00 AM
RNS
Destiny Pharma Appoints Stephanie Bewick as CBO
05 Jan 2021 07:00 AM
RNS
Phase 2b trial of XF-73 completes recruitment
23 Dec 2020 02:09 PM
RNS
Grant of share options
22 Dec 2020 07:00 AM
RNS
Update on the recently acquired NTCD-M3 programme
01 Dec 2020 05:23 PM
RNS
Holding(s) in Company
30 Nov 2020 02:00 PM
RNS
Holding(s) in Company
26 Nov 2020 10:50 AM
RNS
Result of General Meeting and Total Voting Rights
25 Nov 2020 07:00 AM
RNS
Result of Open Offer
09 Nov 2020 04:25 PM
RNS
Fundraising and Acquisition
12 Oct 2020 07:00 AM
RNS
Clinical Study Patient Recruitment Update
17 Sep 2020 07:00 AM
RNS
Interim results for the 6 months ended 30 Jun 2020
17 Sep 2020 07:00 AM
RNS
Update on Phase 2b clinical study of XF-73
10 Sep 2020 07:00 AM
RNS
Notice of Results
07 Sep 2020 04:40 PM
RNS
Second Price Monitoring Extn
07 Sep 2020 04:35 PM
RNS
Price Monitoring Extension
07 Sep 2020 02:06 PM
RNS
Second Price Monitoring Extn
07 Sep 2020 02:01 PM
RNS
Price Monitoring Extension
07 Sep 2020 11:06 AM
RNS
Second Price Monitoring Extn
07 Sep 2020 11:01 AM
RNS
Price Monitoring Extension
07 Sep 2020 09:05 AM
RNS
Second Price Monitoring Extn
07 Sep 2020 09:00 AM
RNS
Price Monitoring Extension
07 Sep 2020 07:00 AM
RNS
Collaboration to co-develop treatment for COVID-19
11 Aug 2020 07:00 AM
RNS
Positive interim safety review of XF-73 phase 2b
27 Jul 2020 07:00 AM
RNS
Update on Phase 2b clinical study of XF-73
15 Jul 2020 07:00 AM
RNS
Destiny Pharma notes launch of AMR Action Fund
19 Jun 2020 11:00 AM
RNS
Cancellation and Grant of Options
10 Jun 2020 12:30 PM
RNS
Result of AGM
09 Jun 2020 07:00 AM
RNS
Grant awarded for Cardiff University collaboration
12 May 2020 03:15 PM
RNS
Posting of Annual Report and Notice of AGM
04 May 2020 07:00 AM
RNS
Independent review supports the potential of XF-73
29 Apr 2020 07:00 AM
RNS
Final Results
24 Apr 2020 07:00 AM
RNS
Notice of Results
03 Mar 2020 07:00 AM
RNS
Clinical and Business Update
20 Jan 2020 07:00 AM
RNS
Update on the development of XF drug formulations
17 Dec 2019 07:00 AM
RNS
APSIC guidelines recommend decolonising S. aureus
02 Dec 2019 07:00 AM
RNS
Directorate Change
02 Dec 2019 07:00 AM
RNS
Destiny to present at UK-China AMR Workshop
15 Nov 2019 07:30 AM
RNS
Presentation at the Investival Showcase

Destiny Pharma is a biotechnology company that develops and sells new medicines to prevent serious infections.

Destiny Pharma share price launched on AIM on August 18, 2017.

UK 100